Literature DB >> 29324477

Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Elaine Barfield1, Robbyn Sockolow1, Edward Hoffenberg2, Shehzad Saeed3, Sandra Kim4, Leah Siebold4, Joseph Picoraro5, Jonathan Moses6, Dana Dykes7, Andrew Grossman8, Ghassan Wahbeh9, K T Park10.   

Abstract

The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease. Patients in North America are increasingly denied coverage by payers based on "place of service" codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with inflammatory bowel disease receiving non-hospital-based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29324477      PMCID: PMC5866197          DOI: 10.1097/MPG.0000000000001890

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  24 in total

1.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors:  Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

3.  Academic achievement, attendance, and school-related quality of life in pediatric inflammatory bowel disease.

Authors:  Laura M Mackner; Robert M Bickmeier; Wallace V Crandall
Journal:  J Dev Behav Pediatr       Date:  2012-02       Impact factor: 2.225

Review 4.  Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Authors:  K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 5.  Premedication Use Before Infliximab Administration: A Cross-sectional Analysis.

Authors:  Joseph Picoraro; Gabriel Winberry; Corey A Siegel; Wael El-Matary; Jonathan Moses; Andrew Grossman; K T Park
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

6.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

7.  Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.

Authors:  Paul A Rufo; Lee A Denson; Francisco A Sylvester; Eva Szigethy; Pushpa Sathya; Ying Lu; Ghassan T Wahbeh; Laureen M Sena; William A Faubion
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-07       Impact factor: 2.839

Review 8.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  The incidence and management of infusion reactions to infliximab: a large center experience.

Authors:  Adam Cheifetz; Michelle Smedley; Sara Martin; Monica Reiter; Grace Leone; Lloyd Mayer; Scott Plevy
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

10.  Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.

Authors:  Sabine Kuin; Suzan B Stolte; Gijs R van den Brink; Cyriel Y Ponsioen; Paul Fockens; Geert R D'Haens; Mark Löwenberg
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-02       Impact factor: 2.566

View more
  4 in total

1.  Alternate Settings for Infusions in Inflammatory Bowel Disease Patients: Homing in on Optimal Care.

Authors:  Sasan Mosadeghi; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

2.  Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.

Authors:  Marc Fenster; Ryan C Ungaro; Robert Hirten; Zane Gallinger; Louis Cohen; Ashish Atreja; Saurabh Mehandru; Jean-Frederic Colombel; Benjamin L Cohen
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-22       Impact factor: 11.382

3.  Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit.

Authors:  Kelly C Sandberg; Janet N Lucien; Denise Stoll; Erica Yanney; Adam Mezoff
Journal:  Pediatr Qual Saf       Date:  2019-01-21

Review 4.  Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist.

Authors:  Toni Docherty; Jennifer J Schneider; Joyce Cooper
Journal:  Pharmacy (Basel)       Date:  2020-12-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.